Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432.
Journal Article (Journal Article)
We report on 348 patients ≥ 70 years (median age 78 years) with acute myeloid leukemia (>50% with secondary AML) randomized to receive either 600 mg or 300 mg of tipifarnib orally twice daily on days 1-21 or days 1-7 and 15-21, repeated every 28 days (4 treatment regimens). Responses were seen in all regimens, with overall response rate (CR + CRi + PR) highest (20%) among patients receiving tipifarnib 300 mg twice daily on days 1-21. Toxicities were acceptable. Unless predictors of response to tipifarnib are identified, further study as a single agent in this population is unwarranted.
Full Text
Duke Authors
Cited Authors
- Erba, HP; Othus, M; Walter, RB; Kirschbaum, MH; Tallman, MS; Larson, RA; Slovak, ML; Kopecky, KJ; Gundacker, HM; Appelbaum, FR
Published Date
- March 2014
Published In
Volume / Issue
- 38 / 3
Start / End Page
- 329 - 333
PubMed ID
- 24411921
Pubmed Central ID
- PMC4247790
Electronic International Standard Serial Number (EISSN)
- 1873-5835
Digital Object Identifier (DOI)
- 10.1016/j.leukres.2013.12.001
Language
- eng
Conference Location
- England